AIM： To investigate whether activin regulates the cell proliferation of human gastric cancer cell line SNU-16 through the mRNA changes in activin receptors, Smads and p21^CIP1/WAF1. METHODS： The human gastric cancer...AIM： To investigate whether activin regulates the cell proliferation of human gastric cancer cell line SNU-16 through the mRNA changes in activin receptors, Smads and p21^CIP1/WAF1. METHODS： The human gastric cancer cell lines were cultured, RNAs were purified, and RT-PCRs were carried out with specifically designed primer for each gene. Among them, the two cell lines SNU-5 and SNU-16 were cultured with activin A for 24, 48 and 72 h. The cell proliferation was measured by MTT assay. For SNU-16, changes in ActRIA, ActRIB, ActRIIA, ActRIIB, Smad2, Smad4, Smad7, and p21^CIP1/WAF1 mRNAs were detected with RT-PCR after the cells were cultured with activin A for 24, 48 and 72 h. RESULTS： The proliferation of SNU-16 cells was down regulated by activin A whereas other cells showed no change. Basal level of inhibin/activin subunits, activin receptors, Smads, and p21^CIP1/WAF1 except for activin βB mRNAs was observed to have differential expression patterns in the human gastric cancer cell lines, AGS, KATO III, SNU-1, SNU-5, SNU-16, SNU-484, SNU-601, SNU-638, SNU-668, and SNU-719. Interestingly, significantly higher expressions of ActR IIA and IIB mRNAs were observed in SNU-16 cells when compared to other cells. After activin treatment, ActR IA, IB, and IIA mRNA levels were decreased whereas ActR IIB mRNA level increased in SNU-16 cells. Smad4 mRNA increased for up to 48 h whereas Smad7 mRNA increased sharply at 24 h and returned to the initial level at 48 h in SNU-16 cells. In addition, expression of the p21^CIP1/WAF1 the mitotic inhibitor, peaked at 72 h after activin treatment in SNU-16 cells. CONCLUSION： Our results suggest that inhibition of cell growth by activin is regulated by the negative feedback effect of Smad7 on the activin signaling pathway, and is mediated through p21^CIP1/WAF1 activation in SNU-16 cells.展开更多
目的通过测定隐丹参酮对人胃癌SGC-7901细胞增殖及血管内皮生长因子（VEGF）mRNA的影响,探讨其抗肿瘤的作用机制。方法采用四甲基偶氮唑蓝（MTT）比色法检测隐丹参酮对人胃癌SGC-7901细胞增殖的影响,采用Real Time RT-PCR检测隐丹参酮对...目的通过测定隐丹参酮对人胃癌SGC-7901细胞增殖及血管内皮生长因子（VEGF）mRNA的影响,探讨其抗肿瘤的作用机制。方法采用四甲基偶氮唑蓝（MTT）比色法检测隐丹参酮对人胃癌SGC-7901细胞增殖的影响,采用Real Time RT-PCR检测隐丹参酮对VEGF m RNA表达的影响。结果 20、40、60、80、100μmol/L的隐丹参酮作用于人胃癌SGC-7901细胞6-48 h,其生长和增殖均受到一定程度的抑制;24 h为隐丹参酮对SGC-7901细胞抑制作用的最佳时间,IC50为59.11μmol/L;选取40、60和80μmol/L 3个剂量作用于人胃癌细胞SGC7901 24 h后,60和80μmol/L的隐丹参酮均可下调VEGF m RNA的表达（均P〈0.01）。结论隐丹参酮可抑制人胃癌SGC-7901细胞增殖,并能抑制VEGF mRNA的表达,提示这可能是其抗肿瘤的作用机制之一。展开更多
背景与目的：探讨丹参酮ⅡA（tanshinoneⅡA，TanⅡA）对人胃癌BGC-823细胞增殖及凋亡的影响。材料与方法：采用0～10μg／ml Tan ⅡA分别作用于BGC-823细胞48h及72h，MTT比色法观察药物对细胞生长的抑制效应；2、5、10μg／ml TanⅡA...背景与目的：探讨丹参酮ⅡA（tanshinoneⅡA，TanⅡA）对人胃癌BGC-823细胞增殖及凋亡的影响。材料与方法：采用0～10μg／ml Tan ⅡA分别作用于BGC-823细胞48h及72h，MTT比色法观察药物对细胞生长的抑制效应；2、5、10μg／ml TanⅡA分别作用于细胞72h，应用HE染色、DNA琼脂糖凝胶电泳、流式细胞术分析药物对细胞凋亡的影响。结果：TanⅡA明显抑制BGC-823细胞增殖、诱导细胞凋亡，镜下可见BGC-823细胞明显的凋亡特征性改变；5、10μg／ml Tan ⅡA处理组细胞DNA电泳可见典型的“梯状”条带；FCM结果显示5、10μg／ml TanⅡA处理组细胞，凋亡率分别为（20．60±1．84）％、（31．03±1．47）％，与对照组（5．23±0．39）％比较差异有统计学意义（P〈0．01）。结论：在一定条件下，TanⅡA可抑制人胃癌BGC-823细胞增殖，诱导其凋亡。展开更多
基金Supported by the Research Fund 2003 from the Catholic University of Korea
文摘AIM： To investigate whether activin regulates the cell proliferation of human gastric cancer cell line SNU-16 through the mRNA changes in activin receptors, Smads and p21^CIP1/WAF1. METHODS： The human gastric cancer cell lines were cultured, RNAs were purified, and RT-PCRs were carried out with specifically designed primer for each gene. Among them, the two cell lines SNU-5 and SNU-16 were cultured with activin A for 24, 48 and 72 h. The cell proliferation was measured by MTT assay. For SNU-16, changes in ActRIA, ActRIB, ActRIIA, ActRIIB, Smad2, Smad4, Smad7, and p21^CIP1/WAF1 mRNAs were detected with RT-PCR after the cells were cultured with activin A for 24, 48 and 72 h. RESULTS： The proliferation of SNU-16 cells was down regulated by activin A whereas other cells showed no change. Basal level of inhibin/activin subunits, activin receptors, Smads, and p21^CIP1/WAF1 except for activin βB mRNAs was observed to have differential expression patterns in the human gastric cancer cell lines, AGS, KATO III, SNU-1, SNU-5, SNU-16, SNU-484, SNU-601, SNU-638, SNU-668, and SNU-719. Interestingly, significantly higher expressions of ActR IIA and IIB mRNAs were observed in SNU-16 cells when compared to other cells. After activin treatment, ActR IA, IB, and IIA mRNA levels were decreased whereas ActR IIB mRNA level increased in SNU-16 cells. Smad4 mRNA increased for up to 48 h whereas Smad7 mRNA increased sharply at 24 h and returned to the initial level at 48 h in SNU-16 cells. In addition, expression of the p21^CIP1/WAF1 the mitotic inhibitor, peaked at 72 h after activin treatment in SNU-16 cells. CONCLUSION： Our results suggest that inhibition of cell growth by activin is regulated by the negative feedback effect of Smad7 on the activin signaling pathway, and is mediated through p21^CIP1/WAF1 activation in SNU-16 cells.
文摘目的通过测定隐丹参酮对人胃癌SGC-7901细胞增殖及血管内皮生长因子（VEGF）mRNA的影响,探讨其抗肿瘤的作用机制。方法采用四甲基偶氮唑蓝（MTT）比色法检测隐丹参酮对人胃癌SGC-7901细胞增殖的影响,采用Real Time RT-PCR检测隐丹参酮对VEGF m RNA表达的影响。结果 20、40、60、80、100μmol/L的隐丹参酮作用于人胃癌SGC-7901细胞6-48 h,其生长和增殖均受到一定程度的抑制;24 h为隐丹参酮对SGC-7901细胞抑制作用的最佳时间,IC50为59.11μmol/L;选取40、60和80μmol/L 3个剂量作用于人胃癌细胞SGC7901 24 h后,60和80μmol/L的隐丹参酮均可下调VEGF m RNA的表达（均P〈0.01）。结论隐丹参酮可抑制人胃癌SGC-7901细胞增殖,并能抑制VEGF mRNA的表达,提示这可能是其抗肿瘤的作用机制之一。
文摘背景与目的：探讨丹参酮ⅡA（tanshinoneⅡA，TanⅡA）对人胃癌BGC-823细胞增殖及凋亡的影响。材料与方法：采用0～10μg／ml Tan ⅡA分别作用于BGC-823细胞48h及72h，MTT比色法观察药物对细胞生长的抑制效应；2、5、10μg／ml TanⅡA分别作用于细胞72h，应用HE染色、DNA琼脂糖凝胶电泳、流式细胞术分析药物对细胞凋亡的影响。结果：TanⅡA明显抑制BGC-823细胞增殖、诱导细胞凋亡，镜下可见BGC-823细胞明显的凋亡特征性改变；5、10μg／ml Tan ⅡA处理组细胞DNA电泳可见典型的“梯状”条带；FCM结果显示5、10μg／ml TanⅡA处理组细胞，凋亡率分别为（20．60±1．84）％、（31．03±1．47）％，与对照组（5．23±0．39）％比较差异有统计学意义（P〈0．01）。结论：在一定条件下，TanⅡA可抑制人胃癌BGC-823细胞增殖，诱导其凋亡。
